Role of bevacizumab therapy in the management of glioblastoma

Figures & data

Table 1 Compilation of phase II studies using bevacizumab for recurrent glioblastoma

Patients	Treatment	Radiographic response (MR, PR, CR)	PFS at 6 months	Overall survival
23	BEV + irinotecan^Citation36	61%	30%	Median 9 mos
33	BEV + CT^Citation37	64%	42%	N/A
48	BEV^Citation38	71%	29%	Median 7 mos
85	BEV^Citation41	28%	43%	Median 9 mos
82	BEV + irinotecan^Citation41	38%	50%	Median 9 mos

Abbreviations: PFS, progression-free survival; MR, minor response; PR, partial response; CR, complete response; BEV, bevacizumab; CT, variable cytotoxic chemotherapy.

Table 2 Compilation of selected phase II studies of cytotoxic drugs for treatment of recurrent glioblastoma

Treatment	Radiographic response (SD, MR, PR, CR)	MTPa
BCNU^Citation42^–^Citation44	29	22
Procarbazine^Citation45,Citation46	27–33	30
Carboplatin^Citation47	40	20
Temozolomide^Citation46	46	20

a MTP, median time to tumor progression for the SD and responding patients.

VredenburghJJDesjardinsAHerndonJE2ndPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res20071341253125917317837

 PubMed Web of Science ®Google Scholar

NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology2008701077978718316689

 PubMed Web of Science ®Google Scholar

KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704

 PubMed Web of Science ®Google Scholar

FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927

 PubMed Web of Science ®Google Scholar

LevinVAChemotherapy of primary brain tumorsNeurol Clin1985348558663001491

 PubMed Web of Science ®Google Scholar

LevinVAWilsonCBNitrosourea chemotherapy for primary malignant gliomasCancer Treat Rep1976606719724954010

 PubMedGoogle Scholar

RodriguezLAPradosMSilverPLevinVAReevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumorsCancer19896412242024232555038

 PubMed Web of Science ®Google Scholar

YungWKAlbrightREOlsonJA phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBr J Cancer200083558859310944597

 PubMed Web of Science ®Google Scholar

YungWKMechtlerLGleasonMJIntravenous carboplatin for recurrent malignant gliomas: a phase II studyJ Clin Oncol1991958601849986

 PubMed Web of Science ®Google Scholar